News

Eli Lilly announced this morning that the FDA has approved its oral GLP-1, orforglipron, which the company is marketing under the brand name Foundayo. The competition between Foundayo and oral Wegovy is expected to be fierce.

A new preclinical study found that inhibiting the enzyme LSD1 can activate the skin’s immune system and suppress tumor growth, pointing to a potential new topical treatment for skin cancer.

A study published March 20 in Nature found that a mechanosensitive piezo1–IL-33 signaling pathway in vascular endothelial cells is associated with pulmonary fibrosis and may represent a potential therapeutic target.

Researchers found that lung function showed only a weak relationship with quality-of-life outcomes, highlighting perhaps the value of broader patient-reported or caregiver-reported outcomes in clinical care and research.

Van Beek, a clinical

Novo Nordisk is offering the subscriptions through telehealth providers Ro, WeightWatchers and LifeMD. Others are expected to follow.

Get clear, expert-backed answers to the biggest questions surrounding the Great Healthcare Plan, with insights from Emma Wager of KFF and industry experts including Jeffrey Casberg, Lindsay Bealor Greenleaf and Luke Greenwalt. This FAQ breaks down what proposed changes to drug pricing, PBMs, subsidies and insurance coverage could mean for your organization — and what to watch as policies take shape.

Preliminary data from a preclinical study show that vialinin-A, a compound isolated from Chinese mushrooms, is an antioxidant that has an anti-inflammatory effect.

Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most patients over 54 weeks with a generally well-tolerated safety profile.

Adults with moderate atopic dermatitis reported rapid itch relief, better sleep, and improved daily functioning after eight weeks using Opzelura topical cream.

Sunlight can be both harmful and beneficial, meaning it’s important for dermatologists to give personalized advice to each patient, according to this morning’s 2026 American Academy of Dermatology session

A new patient survey reveals gaps in treatment persistence and awareness among patients with vitiligo.

Lack of measures that take into account severity hinders participation by dermatologists, says the University of Iowa Health Care dermatologic surgeon.

Arthropods can cause or mimic a wide range of skin diseases, making accurate recognition, diagnosis and management essential in dermatologic care.

This afternoon’s session emphasized evolving vitiligo management strategies focused on emerging immune-targeted treatments, alongside a growing emphasis on holistic, patient-centered care.

The large dose of brepocitinib, a JAK1/TYK2 inhibitor, showed benefits on a composite score and secondary end points. The FDA has set a PDUFA date for the drug in the third quarter of 2026, according to its developer.

At the American Academy of Dermatology 2026 meeting, dermatology leaders emphasized the growing need for advocacy to address rural access disparities and the escalating impact of climate change on patient care and health systems.

Litifilimab, a monoclonal antibody that reduces type-I interferon production and inflammation, has the potential to be a first-in-class targeted therapy for patients with cutaneous lupus.

Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston, discusses the complexities of figuring out cost-effect acne treatment.

The 2026 American Academy of Dermatology meeting began today in Denver, featuring a keynote conversation this evening with John Legend on wellness, identity and his Loved01 skincare brand.

Studies have shown that routine monitoring for hyperkalemia has limited usefulness, says Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston.

Barbieri, director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital in Boston, provided an update on spironolactone at the American Academy of Dermatology meeting in Denver.

CEO of Veradermics, Reid Waldman, M.D., shared that faster hair growth and shifting patient views on prescription treatments could play a key role in improving adherence and outcomes for pattern hair loss.

At the 2026 American Academy of Dermatology meeting, Reid Waldman, M.D., shared data showing that Veradermics’ investigational oral drug VDPHL01 produced faster, more consistent and greater hair growth than existing minoxidil treatments.

Vitiligo is a chronic autoimmune disease that affects skin pigmentation and, while not painful or contagious, requires greater attention in managed care due to its long-term nature and psychosocial impact.